Thermo Fisher Scientific announced that it will sell its microbiology unit to private‑equity firm Astorg for approximately $1.08 billion. The transaction will be financed with cash and a $50 million seller note and is expected to close in the second half of 2026.
The microbiology business, which generated $645 million in revenue in 2025, provides antimicrobial‑susceptibility testing and culture‑media solutions to clinical, pharmaceutical and food‑industry customers. The unit employs roughly 2,400 people and operates 13 manufacturing and R&D sites worldwide.
Thermo Fisher’s decision to divest the unit is part of a broader strategy to streamline its portfolio and concentrate on higher‑margin life‑sciences solutions. The sale is expected to generate a non‑recurring gain and will dilute adjusted earnings per share by $0.15 in the first full year after closing, while freeing capital for investment in its core biopharma and analytical‑instrument businesses.
In the same week, Thermo Fisher reported first‑quarter 2026 results that beat expectations: revenue rose 6% to $11.01 billion and adjusted EPS climbed 6% to $5.44, a $0.24 beat on analyst estimates. Management raised full‑year guidance, but investors reacted cautiously, citing concerns about the structure of growth—organic revenue was lower than the 3% from acquisitions and 2% from foreign‑exchange tailwinds that helped lift the headline figure.
Astorg, a pan‑European private‑equity firm with a focus on healthcare, plans to scale the microbiology business and accelerate growth, potentially through additional acquisitions. The firm’s expertise in life‑sciences positions it to enhance the unit’s operational performance.
Market reaction to Thermo Fisher’s Q1 earnings was muted: pre‑market trading showed a 4.3% decline, and the stock had fallen 11.02% over the past week and 24.98% over the past 90 days. Analysts pointed to the company’s reliance on inorganic growth and foreign‑exchange gains as key headwinds, raising questions about the sustainability of its organic expansion.
The sale aligns with Thermo Fisher’s portfolio optimization strategy, providing capital for core growth initiatives while allowing Astorg to build a standalone microbiology platform. Investors remain attentive to the company’s ability to sustain organic growth, but the transaction is a clear step toward a more focused, higher‑margin business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.